Thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding or other safety outcomes in hip arthroplasty

Kamphuisen, Pieter W.
October 2008
ACP Journal Club;10/21/2008, Vol. 149 Issue 4, p4
Academic Journal
The article focuses on the findings of two studies regarding the efficacy of anticoagulant thromboprophylaxis with rivaroxaban or enoxaparin in hip anthroplasty. Randomized controlled trials were conducted on patients 18 to 93 years of age and revealed that thromboprophylaxis with rivaroxaban or enoxaparin did not differ for major bleeding in total hip arthroplasty. It states that neither rivaroxaban nor enoxaparin groups differ for abnormalities in liver enzymes in hip anthroplasty.


Related Articles

  • Continue anticoagulation up to 6 weeks after hip replacement surgery.  // Geriatrics;Dec96, Vol. 51 Issue 12, p54 

    Presents abstracts of the articles `Low Molecular Weight Heparin (Enoxaparin) as Prophylaxis Against Venous Thromboembolism After Total Hip Replacement,' by D. Bergquist et al and the `Antithrombotic Strategy After Total Hip Replacement: A Cost-Effectiveness Analysis Comparing Prolonged Oral...

  • Postoperative Versus Preoperative Initiation of Deep-Vein Thrombosis Prophylaxis with a Low-Molecular-Weight Heparin (Nadroparin) in Elective Hip Replacement. Palareti, Gualtiero; Borghi, Battista; Coccheri, Sergio; Leali, Nicoletta; Golfieri, Rita; Montebugnoli, M.; Inghilleri, Giovanni; Ronzio, Alessandro; Barbui, Tiziano; Pogliani, Enrico Maria; Di Nino, Gianfranco; Spotorno, Lorenzo // Clinical & Applied Thrombosis/Hemostasis;Winter1996, Vol. 2 Issue 1, p18 

    The aim of this multicenter, randomized, double-blind study performed in patients undergoing elective hip surgery was to compare the efficacy and safety of prophylaxis with low-molecular-weight heparin (LMWH) (Nadroparin, 7,500 anti-Xa IC units for the first 3 days and 10,000 from the fourth day...

  • Randomized clinical trial of dexketoprofen/tramadol 25 mg/75 mg in moderate-to-severe pain after total hip arthroplasty. McQuay, H. J.; Moore, R. A.; Berta, A.; Gainutdinovs, O.; Fülesdi, B.; Porvaneckas, N.; Petronis, S.; Mitkovic, M.; Bucsi, L.; Samson, L.; Zegunis, V.; Ankin, M. L.; Bertolotti, M.; Pizà-Vallespir, B.; Cuadripani, S.; Contini, M. P.; Nizzardo, A. // BJA: The British Journal of Anaesthesia;Feb2016, Vol. 116 Issue 2, p269 

    Background: The aim was to evaluate the analgesic efficacy and safety of the dexketoprofen/tramadol 25 mg/75 mg fixed-dose combination vs dexketoprofen (25 mg) and tramadol (100 mg) in moderate-to-severe acute pain after total hip arthroplasty.Methods: This was a...

  • Lack of an antagonist to reverse the action of dabigatran. Jolobe, O.M.P. // QJM: An International Journal of Medicine;Feb2012, Vol. 105 Issue 2, p212 

    No abstract available.

  • Oral Thromboprophylaxis Following Total Hip or Knee Replacement: Review and Multicentre Experience with Dabigatran Etexilate. Kendoff, D.; Perka, C.; Fritsche, H. M.; Gehrke, T.; Hube, R. // Open Orthopaedics Journal;2011, Vol. 5, p395 

    The risk of venous thromboembolism (VTE) in patients undergoing total knee or hip replacement surgery is high. As a result, thromboprophylaxis is highly recommended. While current thromboprophylactic agents, such as low molecular weight heparins (LMWH) and vitamin K antagonists, are safe and...

  • Rivaroxaban cost effective in various settings. Joshi, Nitin // PharmacoEconomics & Outcomes News;11/29/2008, Issue 567, p2 

    Recently completed RECORD trials have shown that rivaroxaban has better efficacy and safety than enoxaparin sodium when used prophylactically for venous thromboembolism (VTE) after major orthopaedic surgeries like total hip replacement (THR) and total knee replacement (TKR). Using data from the...

  • Rivaroxaban rates in Russia for preventing VTE after surgery.  // PharmacoEconomics & Outcomes News;6/11/2011, Issue 630, p4 

    The article deals with two studies which examine the effectiveness of rivaroxaban compared with dabigatran and enoxaparin for the prevention of venous thromboembolism after total hip and total knee replacement, presented at the 16th Annual International Meeting of the International Society for...

  • Phase 3 data show rivaroxaban superior to enoxaparin in preventing post-THA VTE.  // Orthopaedics Today/International Edition;Jan/Feb2008, Vol. 11 Issue 1, p11 

    The article discusses research being done on the use of the experimental anticoagulant rivaroxaban for preventing venous thromboembolism in total hip arthroplasty patients. It references a study by Bengt I. Eriksson et al, presented at the 49th Annual Meeting of the American Society of...

  • High complication rate after total knee and hip replacement due to perioperative bridging of anticoagulant therapy based on the 2012 ACCP guideline. Leijtens, Borg; Kremers van de Hei, Keetie; Jansen, Justus; Koëter, Sander // Archives of Orthopaedic & Trauma Surgery;Sep2014, Vol. 134 Issue 9, p1335 

    Introduction: An increasing amount of patients receiving total joint replacement require bridging of long-term anticoagulants. Guidelines, aimed at preventing complications, focus on thromboembolic events but not on bleeding complications. In this retrospective observational study, bleeding and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics